CoCrystal reports Phase I data for HCV candidate CC-31244

CoCrystal Pharma Inc. (OTCQB:COCP) reported data from a Phase Ia/Ib trial in 42 healthy volunteers and 15 patients with HCV genotype 1 infection showing that CC-31244 led to no dose-limiting toxicities (DLTs), discontinuations due to adverse events or serious adverse events.

CC-31244, dosed at 400 or 600 mg once daily or 200 mg twice daily, reduced HCV RNA viral load by 3 log orders from baseline to day 4. At day 6 after the last dose, the average viral load was in the range of 1.7 to 2 log orders below baseline...